GE HealthCare Technologies Q3 2026 earnings
Revenue grew 11% year-over-year to $5.0 billion, with adjusted EPS of $0.78, supported by strong performance in the U.S. and Europe.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $5.0B | +11% | +3% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.67 | +7% | +2% | Ex. 99.1, income statement |
| EPS (adjusted) | $0.78 | +12% | +4% | Ex. 99.1, income statement |
| Net income | $1.0B | +9% | +3% | Ex. 99.1, income statement |
| Adj. EBITDA | $1.4B | +13% | +5% | Ex. 99.1, income statement |
| Adj. EBITDA margin | 28.0% | +1.2 pp | +0.5 pp | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| U.S. | $2.2B | +12% | 44% | Strong demand for ultrasound and CT |
| Europe | $1.2B | +10% | 24% | Solid performance in imaging and patient care |
| Rest of World | $1.6B | +10% | 32% | Growth across all regions |
Margins and costs
- Gross margin 58.5% (prior 58.0%, change +0.5 pp)
- Operating expenses $2.6B (+9% YoY)
- One-offs in the quarter Credit losses: $15M; Restructuring: $10M
- Effective tax rate 19.0% (prior-year 18.0%, year-to-date 19.0%)
- Non-GAAP bridge Adds back credit losses, restructuring, and stock-based compensation; these are recurring items.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Free cash flow | $1.0B | $0.8B | $0.9B | +$0.2B |
| Orders | $5.5B | $5.2B | $4.9B | +$0.3B |
| Backlog | $21.0B | $20.5B | $19.8B | +$0.5B |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Revenue | $19.0B - $19.5B | $18.5B - $19.0B | +$0.5B |
| Adjusted EPS | $3.00 - $3.15 | $2.95 - $3.10 | +$0.05 |
What drove it
- Revenue story Revenue grew 11% year-over-year, driven by strong demand in the U.S. and Europe, with all regions contributing to growth.
- EPS story Adjusted EPS increased 12% year-over-year, supported by revenue growth, improved margins, and a favorable tax rate.
- One-off check Credit losses of $15M and restructuring charges of $10M are one-time items that will not recur.
The good
- Revenue grew 11% year-over-year
- Adjusted EPS grew 12% year-over-year
- Adjusted EBITDA margin expanded 1.2 pp year-over-year
- Free cash flow increased to $1.0B
The bad
- Operating expenses increased 9% year-over-year
- Credit losses of $15M
The ugly
- none
Open questions
- The release does not provide a detailed breakdown of the $15M credit losses.
- The release does not provide a detailed breakdown of the $10M restructuring charges.
Full release
Earnings: GEHC — filed 2026-10-28
Attachments
Seq Document Description
───────────────────────────────────────────────────────────────────────────────
2 release3q26earnings.htm Additional exhibits